1H-indazole-1-sulfonamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 1H-indazole-1-sulfonamide
• 英文别名: indazole-1-sulfonamide
• 化学式: C₇H₇N₃O₂S
• 分子量: 197.217
• InChiKey: AWIDPWYWDZWQGN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  86.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  吲唑 在 氨基磺酰氯 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 以52%的产率得到1H-indazole-1-sulfonamide
  参考文献：
  名称：

  [EN] SULFONYL UREA DERIVATIVES AND THEIR USE IN THE CONTROL OF INTERLEUKIN-1 ACTIVITY
  [FR] DÉRIVÉS DE SULFONYL URÉE ET LEUR UTILISATION DANS LE CONTRÔLE DE L'ACTIVITÉ DE L'INTERLEUKINE -1

  摘要：

  本发明涉及式（I）的化合物及其药用可接受盐、药物组合物、使用方法以及制备方法。本文披露的化合物通过抑制炎症小体抑制IL-1家族细胞因子的成熟，可用于治疗炎症小体活性所涉及的疾病，如自身炎症性和自身免疫性疾病等。

  公开号：

  WO2018015445A1

文献信息

• Substitited indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds, their prepartion and use in medicaments
  申请人：Esteve Laboratorios Dr. Esteve S.A.

  公开号：EP1676841A1

  公开（公告）日：2006-07-05

  The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT6 receptors.

  本发明涉及通式I的取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物，其制备方法，包含所述取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物的药物，以及利用所述取代吲唑磺胺基和2,3-二氢吲唑磺胺基化合物制备药物，该药物特别适用于预防和/或治疗至少部分通过5-HT6受体介导的疾病或疾病。
• INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T))
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20170342062A1

  公开（公告）日：2017-11-30

  Indazole sulfonamide derivatives of formula (I), the pharmaceutically acceptable addition salts thereof, the hydrates and/or solvates thereof, and the use of same as inverse agonists of retinoid-related orphan receptor gamma RORγt are described. Pharmaceutical compositions including such compounds, as well as the use thereof for the topical and/or oral treatment of RORγt receptor-mediated inflammatory diseases, in particular acne, psoriasis and/or atopic dermatitis are also described.

  本发明涉及式(I)的吲唑磺胺衍生物，其药学上可接受的加盐物，其水合物和/或溶剂合物，以及将其用作视黄醇相关孤儿受体伽玛RORγt的逆向激动剂的用途。还描述了包括这些化合物的药物组合物，以及将其用于治疗RORγt受体介导的炎症性疾病，特别是痤疮、银屑病和/或特应性皮炎的局部和/或口服治疗。
• [EN] N-SUBSTITUTED INDAZOLE SULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS<br/>[FR] COMPOSÉS INDAZOLE SULFONAMIDE N-SUBSTITUÉS AYANT UNE ACTIVITÉ SÉLECTIVE DANS LES CANAUX SODIQUES POTENTIEL-DÉPENDANTS
  申请人：MERCK SHARP & DOHME

  公开号：WO2014066491A1

  公开（公告）日：2014-05-01

  Disclosed are compounds of Formula AA and Formula AB: wherein "Heteroaryl-1", RA1, RA2, RB1, and RC are defined herein, which novel compounds have properties for blocking Nav 1.7 ion channels found in peripherial and sympathetic neurons. Also described are pharmaceutical formulations comprising the compounds of Formulae AA and AB or their salts, and methods of treating neuropathic pain disorders using the same.

  本发明涉及AA式和AB式化合物：其中“杂环芳基-1”，RA1、RA2、RB1和RC的定义如本文中所述，这些新型化合物具有阻止周围和交感神经元中发现的Nav 1.7离子通道的特性。还描述了包含AA式和AB式化合物或其盐的制药配方，并且使用它们治疗神经病理性疼痛障碍的方法。
• Chemical compounds
  申请人：Berger Markus

  公开号：US20080207721A1

  公开（公告）日：2008-08-28

  Compounds of formula (I): or a pharmaceutically acceptable salt thereof, compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal).

  化学式为（I）的化合物或其药学上可接受的盐、包含它们的组合物、制备它们的过程以及它们在医疗治疗中的应用（例如在温血动物中调节糖皮质激素受体）。
• Substituted Indazolyl Sulfonamide and 2,3-Dihydro-Indolyl Sulfonamide Compounds, their Preparation and Use in Medicaments
  申请人：Merce Vidal Ramon

  公开号：US20090005417A1

  公开（公告）日：2009-01-01

  The present invention relates to substituted indazolyl sulfonamide and 2,3-dihydroindolyl sulfonamide compounds of general formula I, a process for their preparation, medicaments comprising said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds as well as the use of said substituted indazolyl sulfonamide and 2,3-dihydro-indolyl sulfonamide compounds for the preparation of medicaments, which are particularly suitable for the prophylaxis and/or treatment of disorders or diseases that are at least partially mediated via 5-HT 6 receptors.

  本发明涉及一般式I的取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物，以及它们的制备方法、包含所述取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物的药物，以及利用所述取代的吲唑磺酰胺和2,3-二氢吲哚磺酰胺化合物制备药物，特别适用于预防和/或治疗通过5-HT6受体介导的至少部分疾病或疾病的用途。